Abstract: A device for measuring permeability of a material sample, the device comprising: an input tank (1) configured to store fluid and to supply the fluid to a sample tank (2) positioned below the input tank (1) and configured to hold the material sample, such as to allow the fluid from the input tank (1) to permeate through the material sample; a receptacle (25) positioned under the sample tank (2) to collect drops of fluid permeated through the material sample; and a device (3) for measuring the mass of the drops collected in the receptacle (25) and coupled with a controlling and monitoring device (11) configured to store data on measured mass and measurement times.

Abstract: A device for measuring permeability of a material sample, the device comprising: an input tank (1) configured to store fluid and to supply the fluid to a sample tank (2) positioned below the input tank (1) and configured to hold the material sample, such as to allow the fluid from the input tank (1) to permeate through the material sample; a receptacle (25) positioned under the sample tank (2) to collect drops of fluid permeated through the material sample; and a device (3) for measuring the mass of the drops collected in the receptacle (25) and coupled with a controlling and monitoring device (11) configured to store data on measured mass and measurement times.

Abstract: The invention provides compositions and methods for the detection of Factor XIa or Tissue Factor (TF) activity in a sample using an antibody based clotting time prolongation assay. The invention provides methods for detection of FXIa or TF activity in a sample using a fluorogenic substrate. Further provided herein is a correlation between elevated levels of FXIa and/or TF with inflammation, acute coronary syndrome (ACS), myocardial infarction, coronary artery disease (CAD), heart failure, aortic stenosis, stroke, or transient ischemic attack. The frequency of FXIa and TF activity was substantially lower in individuals with stable coronary artery disease and no history of myocardial infarction. No FXIa or TF activity was observed in healthy individuals.

Abstract: The invention provides compositions and methods for the detection of Factor XIa or Tissue Factor (TF) activity in a sample using an antibody based clotting time prolongation assay. The invention provides methods for detection of FXIa or TF activity in a sample using a fluorogenic substrate. Further provided herein is a correlation between elevated levels of FXIa and/or TF with inflammation, acute coronary syndrome (ACS), myocardial infarction, coronary artery disease (CAD), heart failure, aortic stenosis, stroke, or transient ischemic attack. The frequency of FXIa and TF activity was substantially lower in individuals with stable coronary artery disease and no history of myocardial infarction. No FXIa or TF activity was observed in healthy individuals.